Bristol-Myers Squibb Co has reported positive results for a checkpoint inhibitor combination therapy in patients with a specific type of metastatic colorectal cancer. It combines Opdivo (nivolumab), a PD-1 inhibitor, and Yervoy (ipilimumab), an inhibitor of CTLA-4.
